Title page

Title: Changing species dynamics and species-specific associations observed between Anopheles and Plasmodium genera in Diebougou health district, southwest Burkina Faso

Authors: Lado P¹, Gray LI¹, Sougué E⁴, Knight AL¹, Sorensen M¹, Leon AS¹, Ring ME¹, Pugh G¹, Randall JC¹, Coffin KL¹, Hemming-Schroeder E¹, Goodwin J², Wade M², Sproch H², Ouédraogo COW⁴, Dah SR⁴, Somé AF⁴, Dabiré RK⁴, Parikh S², Foy BD¹*

¹Center for Vector-borne Infectious Diseases, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA; ²Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA; ³Center for Innovative Design and Analysis, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; ⁴Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso; [^]These authors contributed equally; *Corresponding Author

Abstract

The prevalence of malaria parasite species in parts of Africa is rapidly changing and influenced by detection methods. The natural vector competence and vectorial capacity of African anophelines for human Plasmodium species has only been well described for P. falciparum and is unclear in the context of mixed and non-falciparum infections. Over the course of two clinical trials (2015 and 2019-2020) testing ivermectin for malaria control in the same region of Burkina Faso, we sampled participants' blood and their households for Anopheles spp. mosquitoes and tested these samples for *Plasmodium* species. *Plasmodium* prevalence in participants and their blood samples was high in both trials. While P. falciparum mono-infections comprised most infections in the 1st trial, mixed and non-falciparum infections comprised 27% of infections in the 2nd trial, with notable changes in species present within participants over time. Furthermore, An. gambiae s.l. was the main vector captured, but An. funestus mosquitoes were unexpectedly prevalent in the 2nd trial, and we found that parasite species prevalence differed in abdominal and head+thorax tissues of these two vector species. Most notably, P. falciparum sporozoites were significantly more prevalent than other parasite species in An. gambiae s.l. while P. ovale sporozoites were significantly more prevalent than other parasite species in An. funestus. Our data suggest differential vector competence for *Plasmodium* species at the study site, which may significantly impact malaria epidemiology, disease prevalence and control efforts.

Introduction

Malaria, caused by *Plasmodium* parasites transmitted by *Anopheles* mosquitoes, is one of the most prevalent infectious diseases in Africa and other parts of the tropics. Of the estimated 249 million cases worldwide, 48.5% occur in West Africa. Burkina Faso is among the most affected countries, ranking 6th in malaria cases and 9th deaths globally (1). Efforts to control the disease burden in the country, similar to other high transmission countries in West Africa, includes using point-of-care (POC) rapid diagnostic tests (RDT) and treatment with artemisinin-based combined therapies (ACT), intermittent preventative treatment in pregnancy (IPTp), and use of seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ). To control transmission, health authorities perform community distributions of insecticide-treated bed nets (ITN) approximately every 2-4 years, which more recently includes distribution of nets containing more than one chemical (dual-chemistry nets), and less often conduct indoor residual spraying (IRS) of insecticides in specific regions (2, 3). Despite these efforts, the malaria burden in Burkina Faso has remained high with increasing incidence for nearly a decade (4, 5).

Potential causes for the intransigence of malaria in Burkina Faso despite these intensive control efforts are many. Socioeconomic factors such as high rates of poverty, limited community uptake and/or compliance with parasite and vector control tools, political upheaval with high migrant flows, and extensive artisanal gold mining across the country all likely contribute to the current situation (6-11). Within- and between-species parasite diversity is also underappreciated and represents an additional challenge of malaria control in high burden countries. Infections with a diversity of genotypic clones of *Plasmodium falciparum* (*Pf*) are common in such settings and correlated to higher malaria incidence among young children in many settings (12-14). In center-west Burkina Faso, higher diversity (multiplicity of infection; MOI) of *Pf* genotypes among those presenting with malaria correlated with periods of higher malaria incidence, and overall MOI decreased with advancing age (15). In southwestern Burkina Faso, using amplicon deep sequencing, we recently demonstrated that asymptomatic individuals harbored a mean of 3.1 distinct *Pf* clones per sampling timepoint spanning across wet and dry seasons, each of which could theoretically have different genetics relating to antimalarial drug resistance, immunogenicity, or other factors relating to disease processes (16).

Parasite species diversity also complicates malaria control, but a recognition of the scope of such diversity within different African regions is only recently emerging. Reports over the past several years have demonstrated unexpected or increasing prevalence of *Plasmodium malariae* (*Pm*), with its unique 72-hour life cycle, and *P. ovale* (*Po*) species *and P. vivax* (*Pv*) with their dormant hypnozoite stages in certain regions (17-19). More limited data from West Africa suggest unexpected prevalence or increases in non-falciparum species in parts of Burkina Faso and other countries (20-22). The lack of detection of non-falciparum species is not surprising because these species tend to maintain lower peripheral parasite densities and therefore are less likely to be detected by microscopy and RDTs (23-25). In addition, African countries nearly universally lack treatment policies which support anti-relapse treatment of dormant hypnozoites of *Po* species and *Pv*, leaving a persistent and unaddressed reservoir within the continent (26).

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128129

130

131

132

On the vector side, there is similarly high diversity both within and between mosquito species across Burkina Faso which varies from the dry Sahel ecozone in the north with a short but intense rainy season to the Sudanian ecozone in the south with a longer rainy season (27-37). Anopheles gambiae s.s. and An. coluzzi typically have the highest human biting rates in rural and semi-rural areas during the rainy seasons (38, 39), while An. arabiensis drives malaria transmission in urban centers especially during the dry seasons (32). In other landscapes, different species can be the primary vectors, including An. funestus group species around areas with more permanent water sources such as dams, swamps and ponds (39-42), and An. nili which breeds along the edges of rivers and streams in the south (43). Highly zoophagic and exophagic vectors such as An. squamosis, An. rufipes, An. coustani, and An. pharoensis can also be prevalent across landscapes in the south (43). These diverse vector species and their varied bionomics can hamper vector control efficacy. For example, exophilic and exophagic behaviors that limit exposure to ITN and IRS insecticides, plus increasing insecticide resistance among these vectors due to exposure from both agriculture and malaria vector control efforts, may be hampering the success of the limited vector control tools available (44).. The complexity of parasite transmission from these diverse vectors also likely fosters malaria risk. For example, malaria risk increases with vector density and blood feeding rates among persons with low ITN use (45), and infection intensity and high MOI in different vector species can also drive differential malaria risks or infections with unique genotypes (16, 46-49)

To develop new malaria control tools that might better control malaria in Burkina Faso, we have conducted cluster-randomized control trials in the southwestern Diebougou district to test if ivermectin mass drug administrations (MDA) can reduce malaria incidence. Ivermectin is a widely used endectocide that exhibits mosquitocidal activity (50). The drug's strong safety profile in humans and broad-spectrum anti-parasitic effects has allowed for its use in MDA to control neglected filarial diseases (51), and ongoing efforts to test its ability to reduce the survival of malaria vectors and limit malaria transmission (52-57). The first trial in Burkina Faso, termed Repeat Ivermectin Mass Drug Administrations for control of Malaria (RIMDAMAL), was conducted from July to November in 2015 and evaluated repeated low dose ivermectin MDA given at 3-week intervals in treatment clusters compared to a single MDA in control clusters (58), while the second trial, termed RIMDAMAL II, occurred in the same region over two consecutive rainy seasons (from July to November in both 2019 and 2020) and evaluated high dose ivermectin or placebo MDA given monthly (59). Additionally, in RIMDAMAL II, MDAs were operationally paired with SMC distribution to children 3-59 months old in all clusters, which was first implemented in the study area in 2018, in between the time of the two RIMDAMAL trials. The RIMDAMAL trials are among several other cluster-randomized control trials that have tested or are in the process of testing if ivermectin MDA can reduce malaria incidence or parasite prevalence among participants in treated communities (60-62).

The outcomes of the RIMDAMAL trial have been published, and the primary and secondary outcomes of the RIMDAMAL II trial will be presented elsewhere. In the process of analyzing the parasite and vector samples collected from these trials, we observed noticeable differences in the prevalence of different parasite species' infecting participants between the first and second

trial, some of whom participated in both trials. Most notably, in RIMDAMAL II, we observed significant associations of specific vector species with different *Plasmodium* species that are suggestive of differences in vector competence and/or vectorial capacity for certain parasite species. In sub-Saharan Africa (SSA), despite *Pf* being the species most frequently detected and responsible for the majority of clinical cases (63), *Po* and *Pm* can significantly contribute to malaria epidemiology and have been observed to occur at high prevalence in parts of several countries (18, 19, 21, 64-73) or increasing in prevalence over longitudinal studies within a country (20). The data presented here shed light on vector-parasite interactions that may influence malaria epidemiology observations in these and other studies.

Results

133

134

135

136

137

138

139

140

141

142143144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

Organization and timelines surrounding the RIMDAMAL trials

The health district of Diebougou is in the southwest region of Burkina Faso in Bougouriba province. The district has been conducting yearly MDA with single dose ivermectin (150 µg/kg) and albendazole (400 mg/kg) in all its communities for more than a decade to control onchocerciasis and lymphatic filariasis. The RIMDAMAL trial was conducted during the 2015 rainy season in 8 clusters (villages) in the health district, while the RIMDAMAL II trial was conducted during the 2019 and 2020 rainy seasons in 14 clusters of the district. Trial designs, cluster selection and allocation in both trials are described elsewhere (58, 59). Briefly, in both trials, clusters were randomized 1:1 between the treatment and control arms, and the trial organizations and treatments and controls were different, however four clusters were common among the two trials (Table 1). In RIMDAMAL, repeated low dose ivermectin MDA (single oral dose, 150 µg/kg) was given at 3-week intervals in treatment clusters and compared to a single MDA at the start of the trial in control clusters, while the RIMDAMAL II trial occurred over two consecutive rainy seasons and repeated high dose ivermectin MDA (1 oral dose daily for 3 days: 300 µg/kg) was given at 1-month intervals in treatment clusters compared to placebo MDA on the same schedule in control clusters. Furthermore, in RIMDAMAL II, MDA was operationally paired with SMC distribution to children between 3-59 months old in all clusters. which was instituted as national policy starting in 2017. A third, unrelated, cluster randomized trial called the REACT trial was conducted from 2016-18 by a few of the authors, which had one trial arm including ivermectin treatment of cattle, goats and sheep in the 2017 rainy season and occurred in villages of the Diebougou health district that were not part of the RIMDAMAL II trial (74, 75). District ITN distributions occurred in 2016 with standard pyrethroid-based nets, and at the end of 2019 (between October 29-November 2) with new dual-chemistry (alphacypermethrin and chlorfenapyr) Interceptor® G2 nets to better control insecticide-resistant malaria vectors. An analysis of Normalized Difference Moisture Index (NDMI), a measure of vegetation moisture content and indicator of land surface wetness, across the study areas from 2015-2020 revealed marked interannual variation as well as variation between clusters (Figure 1). Overall, the 2015 RIMDAMAL trial was conducted during a drier rainy season of those analyzed for the study area, while both rainy seasons of RIMDAMAL II (2019 and 2020) were relatively wet (Figure 1). NDMI was selected for analysis because it provides information on both temporal precipitation and landscape heterogeneity which may correspond to differences in larval habitat abundance (76).

Event	Year									
	2015	2016	2017	2018	2019	2020				
RIMDAMAL	July 17 – November 22 Treatment									
trial	DG, KK, KP, TJ Control DK, LM, ML, TG									
					July 26 – November 13	July 20 – November 9				
RIMDAMAL II trial					Treatment BG, DK , DT, GB, KP , KS, <u>SG</u>	Treatment BG, DK , DT, GB <u>KP</u> , <u>KS, SG</u>				
					Control (Placebo) DB, DL, MT, NB, NV, TG , TJ	Control (Placebo DB, DL, MT, NB, NV, TG, TJ				
REACT trial			September ivermectin treatment of cattle. goats and sheep in 6 villages of the health district.							
SMC distribution				July-October SP-AQ	July-October SP-AQ	July-October SP-AQ				
ITN		July		700	October 29- November 2	27.719				
distributions		deltamethrin ITN			α-cypermethin + chlorfenapyr ITN					

Differences in the prevalence of *Plasmodium* species between participants of the RIMDAMAL and RIMDAMAL II trials.

The prevalence of blood smear slides from the 2015 RIMDAMAL trial that were positive by microscopy for *Plasmodium* spp. and for different *Plasmodium* species was previously reported, as was the multiplicity of infection and molecular force of infection in *Pf* positives (58). Here we report data using molecular analyses on 90 archived blood samples taken from 24 children aged 0-5 years (split equally from 2 clusters in each arm) who had a fever or history of fever in the prior 24 hours. Of those, 39% (35/90) of tested samples were positive for *Plasmodium* species and all were *Pf* mono-infections. Overall, 71% (17/24) of these tested children had a molecularly confirmed parasitemia at least once during the trial (Table 2).

In contrast, in the RIMDAMAL II trial, infections with multiple different *Plasmodium* species were commonly detected in human dried blood spots from 70 randomly chosen RIMDAMAL II participants (split equally from 3 clusters in each arm, and between age grouping and sex) from our cross-sectional cohort (3 villages per arm) sampled over 2 seasons (2019-2020) (Table 2). Of the 405 samples tested, 56% (225/405) were positive for *Plasmodium* species, and of these 72% (161/225) were *Pf* mono-infections and 28% (64/225) were *Pf*-mixed or non-falciparum infections (12% (27/225) Pf+Pm co-infections, 5% (12/225) Pm mono-infections, 5% (12/225) Pf+Po co-infections, 2% (4/225) Po mono-infections, 0.4% (1/225) Pf+Pv co-infections, and 3% (7/225) Pf+Po+Pm infections). Children 0-5 years old (who took SMC in the trial) more often had negative blood samples over the trial period relative to participants \geq 6 years old (61% vs. 34%;

P < 0.0001) and tended to less often be infected with at least one non-falciparum species over the trial period relative to participants \geq 6 years old (56% vs. 33%; P = 0.0871). Across all age groups, most non-falciparum infections were detected in one or two cross-sectional blood samples obtained from individuals throughout the trial period (Figure 2).

Table 2. Molec	cular detection	of Plasmodi	um parasites	from participa	ants of the RI	MDAMAL trial	s.									
Trial	Participants (any longitudinal sample)							Participants' samples								
	ACD cohort (0-5 yrs old)* Participants ≥ 6 yrs old						ACD cohort (0-5 yrs old)*				Participants ≥ 6 yrs old					
	Pf	Pf+nPf	n <i>Pf</i>	neg	Pf	Pf+nPf	n <i>Pf</i>	neg	Pf	Pf+nPf	n <i>Pf</i>	neg	Pf	Pf+nPf	n <i>Pf</i>	neg
RIMDAMAL	71% (17/24)	0% (0/24)	0% (0/24)	29% (7/24)	-	-	-	-	39% (35/90)	0% (0/90)	0% (0/90)	61% (55/90)	-	-	-	-
RIMDAMAL II	59% (16/27)	22% (6/27)	11% (3/27)	7% (2/27)	37% (16/43)	53% (23/43)	2% (1/43)	7% (3/43)	30% (47/156)	5% (8/156)	4% (6/156)	61% (95/156)	46% (114/249	16% (40/249)	4% (10/249)	34% (85/249

Anopheles speciation and blood meal analysis

RIMDAMAL entomology data were previously reported (58). Briefly, 2,801 mosquitoes were captured via indoor aspirated of which 99% (2,784/2,801) were morphologically identified as *An. gambiae* s.l. These were blood fed mosquitoes that were separated into 1) head+thorax tissue that were previously homogenized and used in sporozoite ELISA assays to detect *Pf* circumsporozoite (CSP) protein, and into 2) bloodfed abdomens that were squashed onto filter papers cards but then used in other experiments.

In RIMDAMAL II, a total of 7,942 anopheline mosquitoes were collected (2019, n = 5,827; 2020, n = 2,115) of which the majority were indoor-captured blood-feds that were held in assays to measure their survival over time. Morphological identification determined the majority to be *An. gambiae* sensu lato (s.l.) (85%; 6,745/7,942), with approximately twice the number captured in 2019 (n = 4,679) as compared to 2020 (n = 2,066). The remainder were *An. funestus* group mosquitoes (15%; 1,197/7,942) of which 96% (1,148/1,197) came from 2019. A subset of *An. gambiae* s.l. mosquitoes were further speciated using molecular methods (n= 354). The majority were identified as *An. gambiae* (79.4%), followed by *An. coluzzi* (15.5%) and *An. arabiensis* (5.1%). Similarly, a subset of *An. funestus* group mosquitoes were further speciated (n = 251) and the majority were identified as *An. funestus* (96.4%), while a small portion were identified as *An. rivulorum* (3.2%) and *An. leesoni* (0.4%).

Blood meal analysis was performed on bloodfed mosquito abdomens from a subset of *An. gambiae* s.l. and *An. funestus* complex mosquitoes (n = 171 and 64, respectively). Human blood meals were detected in most samples from both *An. gambiae* s.l. (81%) and *An. funestus* (68%) (P = 0.0559). Cattle blood meals were the next most abundant but were significantly more prevalent in *An. funestus* (23%; 15/64) than in *An. gambiae* s.l. (6%; 11/171) (P = 0.0006). Dog, goat, and pig blood meals were detected in both mosquito species, but were uncommon (Figure 3).

Prevalence of *Plasmodium* parasites species detected in bloodfed and unfed mosquito head-thorax tissues from both trials.

235

236

237

238

239

240241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259260

261

262

263

264

265

266267

268

269

In RIMDAMAL, the overall sporozoite rate over the intervention period and across arms was 4.8% (62/1759; *An. gambiae* s.l. only, head-thoraxes tested by CSP-ELISA) (Table 3).

Trial	Trial Mosquito species		Sporozoite rate over trial	P value
RIMDAMAL	An combine of	Control	3.4% (33/961)	-
KIIVIDAIVIAL	An. gambiae s.l.	Treatment	3.4% (33/961) 3.6% (29/798) 5.3% (74/1399) 4.3% (48/1129) 20.4% (23/113) 11% (15/136) 6.4% (97/1512)	0.8207
	An combine of	Control	5.3% (74/1399)	-
	An. gambiae s.l.	Treatment	4.3% (48/1129)	0.2626
RIMDAMAL II	An. funestus	Control	` ,	-
KIIVIDAIVIAL II	An. lunestus	Treatment	11% (15/136)	0.0416
	An. gambiae s.l. +	Control	6.4% (97/1512)	-
	An. funestus	Treatment	5% (63/1265)	0.1201

From RIMDAMAL II, a total of n = 2,777 mosquito head-thorax samples (n = 2,528 An. gambiae s.l and n = 249 An. funestus) were screened for Plasmodium sporozoites using species-specific qPCR. The overall sporozoite rate over the intervention period and across arms was 5.8 % (n = 160/2,777). In An. gambiae s.l. the overall sporozoite rate across arms was 4.8 % (n = 122/2528) and the most common *Plasmodium* species of sporozoites detected among positives was Pf mono-infections (65%; 79/122), followed by Po mono-infections (25%; 31/122), Pm mono-infections (8%: 10/122), and only two mixed species infections (both Pf+Po co-infections; Figure 4c). In contrast, An. funestus had a significantly higher overall sporozoite rate over the intervention period than An. gambiae s.l. (15.3%; 38/249; P < 0.0001). Also, in contrast to An. gambiae s.l., the most prevalent sporozoite species detected among positives of An, funestus was Po (63.2%;24/38), followed by Pf and Pm, both at 18.4% (7/38 each) (Figure 4f). Thus, in the RIMDAMAL II trial, the Pf sporozoite rate in An. gambiae s.l. was significantly greater than in An. funestus (P <0.0001), and the Po sporozoite rate in An. funestus was significantly greater than in An. gambiae s.l. (P <0.0001) from mosquitoes captured in the same villages and houses over the same dates. Furthermore, while the overall sporozoite rates and those from An. gambiae s.l. captured in clusters from treatment or control arms were not significantly different from one another, sporozoite rates were significantly higher (~2 fold) in the control arm relative to the intervention arm for An. funestus (P = 0.0416; Table 3).

Prevalence of *Plasmodium* parasites species detected in bloodfed and unfed mosquito abdomens in RIMDAMAL II

To better understand the observed differences in sporozoite rates between species and treatment arms in RIMDAMAL II, we examined a portion of the stored bloodfed and unfed abdomen samples from each mosquito species and from those that were either sporozoite-positive or sporozoite-negative. Of the 264 *An. gambiae* s.l. bloodfed abdomens tested, 75% (198/264) were positive for at least one *Plasmodium* species (Figure 4a). Approximately half of positives (47%; 93/198) contained parasites of only one species and most often this was *Pf.* However, nearly as many (41%; 81/198) contained mixed parasites consisting of *Pf* plus one or more non-falciparum species. In contrast, of the *An. funestus* bloodfed abdomens tested, a

significantly lower proportion were *Plasmodium*-positive (52.8%; 47/89; P = 0.0002) (Figure 4d), with the majority (87.2%; 41/47; P < 0.0001) containing parasites of a single species of either *Pf*, *Po* or *Pm*. Overall *Plasmodium* spp. prevalence in blood fed abdomens was modestly higher in sporozoite-positive versus sporozoite-negative mosquitoes, regardless of mosquito species (Figure 5). Similarly, mosquitoes captured from treatment arm clusters had a modestly lower prevalence of *Plasmodium* spp. than those captured from control arm clusters (Figure 6).

Most unfed abdomens tested negative for parasites (Figure 4b & 4e), in contrast to the blood fed abdomens of the same species (Figure 4a & 4c). Furthermore, *Plasmodium* species prevalence in these unfed abdomens were higher than, but reflective of, the sporozoite-positive head-thoraxes of the different mosquitoes in that only mono-infections were detected. *Pf* and *Po* infections were approximately equal among the unfed abdomens of these mosquitoes, but *Pm* infections of unfed abdomens were only detected in *An. funestus* (Figure 4b & 4e).

Discussion

The results presented suggest that malaria epidemiology at the study site appears to have changed over a six-year period whereby non-falciparum species have become prevalent, particularly as mixed infections with *Pf*. The data also suggest that vectors species have differential competence for spreading non-falciparum infections, which may be one novel driver explaining changes in malaria species epidemiology. Unfortunately, standard malaria surveillance performed by the national health authorities, and most other malaria studies in the country over the last decade, have focused on tackling the burden of *Pf*, and molecular data on the prevalence of non-falciparum species in Burkina Faso is largely lacking. One other published study, however, similarly reported an increase in non-falciparum infections from 2007-2010 in central-west Burkina Faso in, but entomological indices were not reported (20).

In addition to entomological factors, anthropogenic factors regarding diagnostics and treatment algorithms have likely driven or influenced the epidemiologic changes observed. Most notably, current POC diagnostics suffer from relatively low sensitivity, requiring peripheral densities of ~100-500 parasites/µL for detection, yet most non-falciparum species tend to maintain lower parasitemias that go undetected (17, 18, 23, 24, 77-79). In addition, while microscopy has the advantage of morphologic-based speciation, this is challenging in practice, particularly in the presence of mixed species infection. With regards to RDTs, nearly 80% of RDTs currently procured in sub-Saharan Africa detect only Pf-specific HRP-2 (80-82). While a second less widely available RDT detects both PfHRP-2 and pan-Plasmodium LDH (83-86), its sensitivity is also low at densities below 1000/µL (25, 87-89). Treatment and prevention guidelines also likely impact species prevalence, as most strategies are explicitly geared towards reducing the Pf burden. In West Africa, the implementation of SMC, including at the site of the RIMDAMAL trials in 2018, has proven to have significant impacts on Pf incidence in children, and although it is anticipated that SP-AQ has activity against non-falciparum species, its precise impact on these other species has not been investigated (90-96). Similarly, the impact of ACTs on nonfalciparum species is less well studied, and the near-complete lack of usage of 8aminoquinolines directed at the dormant liver stages of Po and Pv in Africa results in a persisting reservoir of infection even if blood-stage therapy is initiated. In a 2-year study of

malaria prevalence in Niger during and after SMC distributions, cross sectional microscopy surveys detected *Pf* alone in the high and low seasons of year 1, but subsequently detected mixed- and mono-infections with *Po* and *Pm* in year 2 (97). In our RIMDAMAL trials, incidence in 0 to 5 year olds dropped approximately 80% between 2015 and 2019 (58) (ClinicalTrials.gov: NCT03967054), presumably due to SMC commencing in 2018, but parasite prevalence remained exceedingly high in both trials suggesting a limited ability of SMC to affect parasite prevalence in this high transmission setting. Malaria incidence among the child cohort in RIMDAMAL II dropped further in 2020 across both arms, which is likely connected to the activity of dual chemistry nets distributed in both trial arms. It is also possibly that an increase in non-falciparum parasite species at the field site may have contributed to the overall reduction in malaria incidence via our active case detection procedures between the two RIMDAMAL trials given that the pyrogenic thresholds of non-falciparum species are likely to be lower than *Pf* (98) from considerably lower parasitemias and shorter durations of patent infections (23, 24, 99, 100).

The abundance of *An. funestus* in RIMDAMAL II during the 2019 rainy season was unexpected considering our data from previous seasons (39, 41, 58). Typically, this vector increases at the very end of the rainy season and persists through the early, 'cold' dry season (late October - February), a time when *An. gambiae* s.l. populations fall dramatically. Its presence is connected to more permanent water sources with emergent vegetation (42, 101) that remain following the cessation of the seasonal rains. *An. funestus* was highly prevalent at the study site in human landing catches performed during dry season sampling between 2017-8 during the REACT trial (75). Its abnormally high density so early in the year in 2019 may be related to the wetter-than-average rainy season (Figure 1) where it could take advantage of the more abundant, possibly deeper water breeding sites across the landscape due to the excess water. Regardless, the opportunity to catch both *An. gambiae* s.l. and *An. funestus*, especially the blood feds, in the same households over the same timeframes allowed for novel insights into potential differential vector competence between *An. gambiae* and *An. funestus* in our area.

The tested blood fed abdomens of both mosquito species would be expected to contain a mix of newly ingested parasites (both asexual forms and gametocytes) from mostly human blood meals that were taken the night prior to capture, as well a smaller proportion of developing early sporogonic stages in and on the midgut tissues of mosquitoes that were infected from an earlier blood meal. The unfed abdomens, being from host-seeking mosquitoes captured in the same households as the blood feds, provided a measure of the proportion of mosquitoes already containing those developing sporogonic stages, which was 21.6% for *An. gambiae* s.l. and 38.2% for *An. funestus*. Considering the proportions of negative abdominal tissues between blood feds and unfeds, the data suggest *An. gambiae* s.l. are exposed to parasites upon blood feeding nearly twice as often as *An. funestus*, likely from higher human biting rates that we observed from this mosquito, and potentially also from a higher propensity to blood feed on multiple people over a single night (102). The data also show that mixed-parasite species blood meals, which we surprisingly observed often in the human samples too, were present nearly five times as often among *An. gambiae* s.l. than *An. funestus*, but mixed infections were not detected in unfed abdomens of either mosquito species, and only detected twice in thoraxes as

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396 397

398

399

400

401

sporozoites. Dividing the unfed abdomen infection rates by the blood fed abdomen parasite rate can provide a rough approximation of successful midgut infection in the wild for both mosquito species, which was only 29% of the time for An. gambiae s.l. but approximately 72% of the time for An. funestus. Examination of infected unfed abdomens compared to sporozoite infections in the positive head+thorax tissues suggests that successful parasite development from early to late sporogonic forms may be similarly more restrictive in An. gambiae s.l. (22%) than in An. funestus (40%). Lastly, the differences observed in the prevalence of different Plasmodium species across the tissues of the two mosquitoes is notable. These data suggest that while An. funestus was less often exposed to parasites during blood feeding, the exposure was more often as mono-infections and parasite infection was more often successful. Furthermore, An. funestus was preferentially infected with Pm or Po, but complete sporogonic development to sporozoites more often favored Po. In contrast, An. gambiae s.l. captured at the same timepoints and from the same households was more often exposed to parasites during blood feeding and up to 40% may have been mixed-infection exposures, but parasite infections were less successful. Furthermore, midgut infections in An. gambiae s.l. (unfed abdomens) were nearly always of a single parasite species which was typically *Pf* and *Po*, but *Pf* more often successfully developed into sporozoites.

Given these are observational entomological and human data, there are several non-mutually exclusive hypotheses that could explain the findings. Most obviously, data may reflect true vector competence differences of mosquito species for different parasite species, such as parasite exflagellation, fertilization or sporogonic development being enhanced for *Po* in *An*. funestus, or the inverse whereby these are inhibited for Pm and Po in An. gambiae, perhaps via innate immune targeting mechanisms (103). This may be an observation of emergent cospeciation between vector and parasite species. Parasite species sporogony competition, either directly or for resources in the mosquito, may also contributing to preferential vector competence outcomes in one mosquito species over the other (104-108). Lastly, factors influencing vectorial capacity may also help explain some of these observations. The An. funestus we captured blood fed more often on cattle, which may explain some of the parasite prevalence data in blood fed abdomens, but another possibility is that An. funestus preferentially blood fed on human hosts with different parasite species relative to An. gambiae, possibly due to a preference for certain attractive odors given off by the infected host dependent on the parasite species they were infected with (109). Some of the results may also be explained by differences in vector blood meal sizes or vector lifespans, such as if most of the An. funestus mosquitoes are longer-lived and therefore more likely to have non-falciparum sporozoites which develop less rapidly than Pf, or mortality in the field due to certain combinations of parasite and vector, for example if Pm sporogonic development increases An. gambiae s.l. mortality. We are not aware of previous field reports on co-speciation or preferential sporogonic development of certain Plasmodium species over others in different species of vector anophelines. Molecular detection of Plasmodium in mosquitoes captured from the field in African settings remains relatively rare due to the costs of performing qPCR on numerous individual mosquito samples with different molecular probes. More often ELISA assays are used to save costs, but these are often only used with antibodies to Pf or Pv alone (110) and are relatively insensitive and prone to false positives when compared to molecular analyses (111-113). Also, for molecular analyses

of mosquitoes, the most efficient molecular targets are also still being compared (114, 115), as are the dissection methods to ensure the fewest false positives (116). We chose to dissect at the junction of the midgut and abdomen, however, the large differences in parasite prevalence between blood fed abdomens compared to unfed abdomens and head+thoracies suggests our analyses was not overly biased from parasite contamination across mosquito tissues. Regardless, this was a comparative analysis between mosquito species.

Importantly, this study has several limitations. Foremost, these longitudinal data are confined to a single field site and must be tested to determine their generalizability. It is possible that the results are partially related to the ivermectin or other intervention activities occurring at the site. Regarding the human data, we had limitations from our more limited testing of archived samples from the RIMDAMAL trial, including that the blood samples tested were only from symptomatic children. Retrospective molecular analysis of mosquito tissues from the RIMDAMAL trial were also not possible due to the samples having been used in prior assays. Follow-up blood sampling and testing should be performed at the site to determine if the change in prevalence from *Pf* to more non-*falciparum* species persists or increases over time, and if non-*falciparum* infections are correlated with presence of *An. funestus* or increased rainfall during the wet season in other areas. While the entomological data are a measure of natural infection outcomes, the analyses are associative being based on observational data alone and so they should be validated using mosquito feeding assays with the blood from infectious participants.

Conclusion

The data presented here show that malaria parasite species prevalence in humans changed dramatically in the Diebougou health district in southwest Burkina Faso over the period bracketing the two RIMDAMAL trials occurring five years apart, and when SMC was initiated at the site in between the two trials. The parasite species changed from almost exclusively being Pf to a high prevalence of non-falciparum species mixed with Pf or occurring alone. Furthermore, evidence suggests that non-falciparum species were preferentially transmitted by An. funestus while Pf was preferentially transmitted by An. gambiae s.l. These formative studies should be followed up with more rigorous testing of the hypotheses regarding vector competence or vectorial capacity differences for Plasmodium parasites between the different mosquito species and may explain the changing malaria epidemiology in areas of sub-Saharan Africa where a diversity of anopheles vectors exist or are in flux.

Methods

Study area, experimental design, and adult mosquito collection

The Diebougou health district in southwestern Burkina Faso experiences a single long rainy season from approximately June-November (39). The RIMDAMAL trial spanned one rainy season (July-November) in 2015, and RIMDAMAL II spanned rainy seasons (July-November) in two consecutive years, 2019 and 2020 and both were conducted in this health district. Detailed information about both trials is available elsewhere (58, 59). Briefly, in RIMDAMAL, 8 village clusters were studied and 4 were randomized to the intervention arm consisting of 6 ivermectin MDAs (single dose of 150 µg/kg) for eligible participants every 3 weeks over one season, while the other 4 were randomized to the control arm consisting of a single ivermectin MDA (single

dose of 150 µg/kg) for eligible participants at the beginning of the season. In RIMDAMAL II, 14 village clusters were studied and 7 were randomized to the intervention arm consisting of 4 ivermectin MDA (3 consecutive daily doses of 300 µg/kg) for eligible participants once per month over 4 months of the season, while the other 7 were randomized to the control arm consisting of placebo administered in the same manner. To estimate spatiotemporal variations in land surface wetness in the study area, Normalized Difference Moisture Index (NDMI), a measure of vegetation moisture content, was assessed from 2015-2020. NDMI was measured from Landsat 8 Level 2, Collection 2, Tier 1 satellite images at 30-m resolution. Satellite images were obtained from the rainy seasons (May to October) and median NDMI calculated for each year from near infrared and short-wave infrared bands after cloud masking in Google Earth Engine.

Anopheline mosquito sampling in both trials was performed similarly, in 8 households from each village in RIMDAMAL and from 8 households in each of 3 villages per arm in RIMDAMAL II, whereby most mosquitoes captured were resting indoor blood feds and aspirated from walls and ceilings in the mornings, and additional capture of host-seeking mosquitoes was performed using light traps located a single centrally located house per village placed indoors next to a person sleeping under a bed net and outdoors next to a person sleeping in a tent. In RIMDAMAL, mosquito collections occurred on the 2nd week follow each MDA, and in RIMDAMAL II on the 1st and 3rd weeks following each MDA. Participants' blood from these same households was also serially sampled across the intervention periods to allow linking of parasitology and entomology outcomes. After collection, mosquitoes were morphologically identified in the field station as either *An. gambiae* s.l., *An. funestus* complex, or other species, and molecular analyses were performed subsequently in laboratories.

DNA extraction from dried human blood spots

Dried blood spots (DBS) on filter paper cards were made in RIMDAMAL from active case detection (ACD) cohort children whose blood was sampled during febrile episodes occurring during the trial. DBS from 24 of these randomly chosen participants who were living in the 4 villages that were also enrolled in RIMDAMAL II (Table 1; KP, TJ, DK, TG) and which were also sampled for mosquitoes were tested for *Plasmodium* species. In RIMDAMAL II, serially collected DBS were collected from participants of all ages from households that were also sampled for mosquitoes, and DBS from 100 of these randomly chosen participants were tested for *Plasmodium* species. DNA was extracted from 3mm hole punches of each DBS by incubating them overnight in a 60°C shaking incubator with PBS and proteinase K and the supernatant process with a Mag-Bind Viral DNA/RNA 96 kit (Omega Bio-Tek) using the KingFisher Flex Magnetic Particle Processor (Thermo Fisher Scientific). DNA was eluted in 30 μL of nuclease-free water and stored at -80° C prior to testing.

DNA extraction from RIMDAMAL II mosquito tissues

Female *Anopheline* head+thoraces stored in RNALater® (Thermo Fisher Scientific) were removed from tubes and blotted on absorbent paper to remove excess liquid. Samples were then individually placed in new tubes with 300 µL mosquito diluent containing 20% of FBS, 100 µg/mL of streptomycin, 100 units/mL of penicillin, 50 µg/mL gentamicin, and 2.5 µg/mL

fungizone in PBS. Samples were homogenized by a single zinc-plated, steel 4.5 mm bead for 1.5 minutes at 24 Hz before being centrifuged for 5 minutes at 14,000 x g at 4°C. DNA was extracted from all samples using the Mag-Bind Viral DNA/RNA 96 kit (Omega Bio-Tek) using the KingFisher Flex Magnetic Particle Processor (Thermo Fisher Scientific). DNA was eluted in 30 μL of nuclease-free water and stored at -80°C. Abdomen samples were placed in 2.0 mL tubes with one 4-5 mm steel bead, TL buffer, and proteinase K solution provided by the Mag Bind Blood and Tissue Kit HDQ 96 kit (Omega Bio-Tek). Each sample was homogenized (50 oscillation for 5 minutes), centrifuged (8,000 rpm for 30 seconds), and incubated in a 56°C dry bath overnight. The next day, homogenates were extracted using a KingFisher™ Flex Purification System (Thermo Fisher Scientific). DNA was eluted in 100 uL of nuclease-free water and yields were quantified using a Nanodrop device (ThermoFisher Scientific) to determine the success of extraction. Once quantified, samples were stored at -80°C until further analysis.

Anopheles speciation

Morphological identification of wild-caught *An. funestus* and *An. gambiae* s.l. mosquitoes was done using standard taxonomic key in the field (117, 118). In a MiniAmp PlusThermocycler, *An. gambiae* s.l. were further speciated following PCR assay which amplified a region of the intergenic spacer 2 (119) to identify *An. gambiae*, *An. coluzzii* and *An. arabiensis*. To further speciate mosquitoes belonging to the *An. funestus* complex, a portion of the ITS2 gene was amplified following the method of Koekemoer et al. (120), and subsequently sequenced. The DNA sequences were aligned in Mesquite (121), and the *Anopheles* species was determined by comparing the sequences with those found in the GeneBank nucleotide database.

Plasmodium detection in both human and mosquito samples

To detect the presence of Pf. Po. Pm and Pv in the head+thorax and/or abdomen tissues, two real-time PCRs were done. Pf DNA was detected using the assay described by Hoffman et al. (122), which detects P. falciparum DNA in mosquito tissues by amplifying the var gene acidic terminal sequence (varATS). Po, Pm and Pv were detected following the protocol described by Phuong et al. (123), which targets the 18S rRNA gene. Pf samples that amplified at or before 36 cycles and showed a logarithmic amplification curve were interpreted as positive. The positive controls for Pf were DNA from Plasmodium-infected DBS generated from in vitro culture at various ranges of parasitemia placed on filter paper, from which 3 mm punches were placed in PCR tubes with 70 µL Rapid Extraction Solution (Thermo Fisher Scientific) and rocked overnight at 4°C and the DNA was purified using the same procedure as described for head+thorax. Negative controls were DNA extracts from malaria-negative DBS. Po, Pm and Pv were detected following the protocol described by Phuong et al. (123), which involved using species-specific forward primers and probes targeting the 18S rRNA gene. Po was identified using a probe labeled with VIC at the 5' end and a minor groove binding quencher at the 3' end. Pv was detected using a probe labeled with TAMRA at the 5' end and a BHQ-2 quencher at the 3' end. Pm was identified using a probe labeled with FAM at the 5' end and a minor groove binding quencher at the 3' end. The same reverse primer was used for all species identification. Nuclease-free water served as the negative control, while linearized, clean DNA from the plasmid clones (MRA numbers 177-180; BEI Resources, NIH, NIAID) acted as both positive

controls. All head+thorax samples that showed logarithmic amplification at or before 36 cycles were interpreted as positive. All PCR reactions were performed in a QuantStudio 3 real-time PCR instrument (Thermo Fisher Scientific).

Blood meal analysis

A conventional PCR followed by a 1.5% electrophoresis gel was done to analyze the host blood meal of mosquito abdomen samples, following the methods described by Kent et al. (124), which amplifies a region of the cytochrome b mitochondrial gene and includes primers to identify blood meals from dog, human, cow, pig, and goat host species. The electrophoresis gel ran at 90 volts for 45 minutes and was imaged on a BIO-RAD ChemiDoc MP Imaging System for analysis.

Statistical analysis

Data was analyzed on GraphPad Prism or R (R-project.org). Chi-square tests and Fisher's exact test were performed, depending on the number of variables. Chi-square test for trend tests for linear trends between variables, while the Fisher's exact test tests for association between variables, and both assess the chances of observing the trend/association in random sampling (GraphPad Prism Version 9.3.1). A P value less than 0.05 was interpreted as statistically significant.

Data Availability

All RIMDAMAL II data will be deposited in ClinEpiDB.org and be available for analysis and download under the terms of set by the website.

Figures




Figure 1. Spatiotemporal variation in wetness inferred from Landsat-8 Normalized Difference Moisture Index (NDMI). Satellite images (Landsat 8 Level 2, Collection 2, Tier 1) were obtained from the rainy seasons (May to Oct) and median NDMI calculated for each year. A) Map of relative wetness at the study site and clusters (outlined in black) B) Temporal variation in mean study site NDMI. Dashed line indicates overall median value. C) Spatial variation in NDMI at each cluster (all years).








Figure 2. Parasite species detected in human dried blood spots from participants of the RIMDAMAL II trial. De-identified codes of participants are shown on the Y-axis. Participants from the 6 clusters (3 ivermectin-treated and 3 placebo-treated) that were randomly selected for entomological and cross-sectional blood sampling during the trial were selected from those who had DBS sampled across the entire study period, and who were equally dispersed between three age groups and genders. Time points on the X-axis refer to the 28-day period in between MDA (mass drug administrations) or approximately 1 week pre- or post- the MDA intervention periods per season.









References

- 750 1. World Health Programme. World Malaria Report 2023. Geneva: 2023.
- 751 2. Institut National de la Statistique et de la Démographie (INSD) PdAaD, Sanitaire (PADS) 752 PNdLclPPel. Enquête sur les indicateurs du paludisme au Burkina Faso. Rockville, Maryland,
- 753 USA: 2018.

- 754 3. Yaro JB, Tiono AB, Ouedraogo A, Lambert B, Ouedraogo ZA, Diarra A, Traore A,
- Lankouande M, Soulama I, Sanou A, Worrall E, Agboraw E, Sagnon N, Ranson H, Churcher
- TS, Lindsay SW, Wilson AL. Risk of Plasmodium falciparum infection in south-west Burkina
- Faso: potential impact of expanding eligibility for seasonal malaria chemoprevention. Sci Rep.
- 758 2022;12(1):1402. doi: 10.1038/s41598-022-05056-7. PubMed PMID: 35082312; PMCID: 759 PMC8791962.
- 760 4. Sangare I, Ouattara CA, Soma DD, Soma D, Assogba BS, Namountougou M, Tougri G,
- Savadogo LB. Spatial-temporal pattern of malaria in Burkina Faso from 2013 to 2020. Parasite
- 762 Epidemiol Control. 2022;18:e00261. doi: 10.1016/j.parepi.2022.e00261. PubMed PMID:
- 763 35859938; PMCID: PMC9289732.
- 5. Bationo C, Cissoko M, Katile A, Sylla B, Ouedraogo A, Ouedraogo JB, Tougri G,
- Kompaore SCB, Moiroux N, Gaudart J. Malaria in Burkina Faso: A comprehensive analysis of
- spatiotemporal distribution of incidence and environmental drivers, and implications for control
- 767 strategies. PLoS One. 2023;18(9):e0290233. doi: 10.1371/journal.pone.0290233. PubMed
- 768 PMID: 37703223; PMCID: PMC10499254.
- 6. US Presidents Malaria Initiative. U.S. President's Malaria Initiative Burkina Faso Malaria Operational Plan FY 2024. U.S. President's Malaria Initiative 2023.
- 77. United Nations Development Programme. Human Development Report 2021-22:
- Uncertain Times, Unsettled Lives: Shaping our Future in a Transforming World. New York: 2022.
- 774 8. Rouamba T, Nakanabo-Diallo S, Derra K, Rouamba E, Kazienga A, Inoue Y, Ouedraogo
- 775 EK, Waongo M, Dieng S, Guindo A, Ouedraogo B, Sallah KL, Barro S, Yaka P, Kirakoya-
- 776 Samadoulougou F, Tinto H, Gaudart J. Socioeconomic and environmental factors associated
- 777 with malaria hotspots in the Nanoro demographic surveillance area, Burkina Faso. BMC Public
- 778 Health. 2019;19(1):249. doi: 10.1186/s12889-019-6565-z. PubMed PMID: 30819132; PMCID:
- 779 PMC6396465.
- 780 9. Guglielmo F, Ranson H, Sagnon N, Jones C. The issue is not 'compliance': exploring exposure to malaria vector bites through social dynamics in Burkina Faso. Anthropol Med.
- 782 2021;28(4):508-25. doi: 10.1080/13648470.2021.1884185. PubMed PMID: 33970705; PMCID:
- 783 PMC7613283.
- 784 10. Allan-Blitz LT, Goldfine C, Erickson TB. Environmental and health risks posed to children
- by artisanal gold mining: A systematic review. SAGE Open Med. 2022;10:20503121221076934.
- 786 doi: 10.1177/20503121221076934. PubMed PMID: 35173966; PMCID: PMC8841918.
- 787 11. Boukaré B. The development impact of "gold rushes" in Mali and Burkina Faso: the
- multifaceted effects of migration on artisanal gold mining sites. In: Fargues F, M. Rango, E.
- 789 Börgnas and I. Schöfberger, editor. Migration in West and North Africa and across the
- 790 Mediterranean, Geneva2020.
- 791 12. Mueller I, Schoepflin S, Smith TA, Benton KL, Bretscher MT, Lin E, Kiniboro B,
- 792 Zimmerman PA, Speed TP, Siba P, Felger I. Force of infection is key to understanding the
- 793 epidemiology of Plasmodium falciparum malaria in Papua New Guinean children. Proc Natl
- 794 Acad Sci U S A. 2012;109(25):10030-5. Epub 2012/06/06. doi: 10.1073/pnas.1200841109.
- 795 PubMed PMID: 22665809; PMCID: 3382533.
- 796 13. Eldh M, Hammar U, Arnot D, Beck HP, Garcia A, Liljander A, Mercereau-Puijalon O,
- 797 Migot-Nabias F, Mueller I, Ntoumi F, Ross A, Smith T, Sonden K, Vafa Homann M, Yman V,
- 798 Felger I, Farnert A. Multiplicity of Asymptomatic Plasmodium falciparum Infections and Risk of

- 799 Clinical Malaria: A Systematic Review and Pooled Analysis of Individual Participant Data. J
- 800 Infect Dis. 2020;221(5):775-85. doi: 10.1093/infdis/jiz510. PubMed PMID: 31585009; PMCID:
- 801 PMC7026891.
- 802 14. Goodwin J, Kajubi R, Wang K, Li F, Wade M, Orukan F, Huang L, Whalen M, Aweeka
- 803 FT, Mwebaza N, Parikh S. Persistent and multiclonal malaria parasite dynamics despite
- 804 extended artemether-lumefantrine treatment in children. Nat Commun. 2024;15(1):3817. doi:
- 805 10.1038/s41467-024-48210-7. PubMed PMID: 38714692; PMCID: PMC11076639.
- 806 15. Sondo P, Derra K, Rouamba T, Nakanabo Diallo S, Taconet P, Kazienga A, Ilboudo H,
- Tahita MC, Valea I, Sorgho H, Lefevre T, Tinto H. Determinants of Plasmodium falciparum
- multiplicity of infection and genetic diversity in Burkina Faso. Parasit Vectors. 2020;13(1):427.
- 809 doi: 10.1186/s13071-020-04302-z. PubMed PMID: 32819420; PMCID: PMC7441709.
- 810 16. Ehrlich HY, Some AF, Bazie T, Ebou CN, Dembele EL, Balma R, Goodwin J, Wade M,
- 811 Bei AK, Ouedraogo JB, Foy BD, Dabire RK, Parikh S. Tracking antimalarial drug resistance
- using mosquito blood meals: a cross-sectional study. Lancet Microbe. 2023. doi:
- 813 10.1016/S2666-5247(23)00063-0. PubMed PMID: 37086737.
- 814 17. Mueller I, Zimmerman PA, Reeder JC. Plasmodium malariae and Plasmodium ovale--
- the "bashful" malaria parasites. Trends Parasitol. 2007;23(6):278-83. doi:
- 816 10.1016/j.pt.2007.04.009. PubMed PMID: 17459775; PMCID: PMC3728836.
- 817 18. Roh ME, Oyet C, Orikiriza P, Wade M, Kiwanuka GN, Mwanga-Amumpaire J, Parikh S,
- 818 Boum Y, 2nd. Asymptomatic Plasmodium Infections in Children in Low Malaria Transmission
- 819 Setting, Southwestern Uganda(1). Emerg Infect Dis. 2016;22(8):1494-8. doi:
- 820 10.3201/eid2208.160619. PubMed PMID: 27434741; PMCID: PMC4982177.
- 821 19. Sendor R, Banek K, Kashamuka MM, Mvuama N, Bala JA, Nkalani M, Kihuma G, Atibu
- J, Thwai KL, Svec WM, Goel V, Nseka T, Lin JT, Bailey JA, Emch M, Carrel M, Juliano JJ,
- Tshefu A, Parr JB. Epidemiology of Plasmodium malariae and Plasmodium ovale spp. in
- Kinshasa Province, Democratic Republic of Congo. Nat Commun. 2023;14(1):6618. doi:
- 825 10.1038/s41467-023-42190-w. PubMed PMID: 37857597; PMCID: PMC10587068 Abbott
- Laboratories, and consulting for Zymeron Corporation, all outside the scope of this study. The
- remaining authors declare no competing interests.
- 828 20. Gneme A, Guelbeogo WM, Riehle MM, Tiono AB, Diarra A, Kabre GB, Sagnon N,
- 829 Vernick KD. Plasmodium species occurrence, temporal distribution and interaction in a child-
- aged population in rural Burkina Faso. Malar J. 2013;12:67. Epub 2013/02/21. doi:
- 831 10.1186/1475-2875-12-67. PubMed PMID: 23421809; PMCID: 3583752.
- 832 21. Heinemann M, Phillips RO, Vinnemeier CD, Rolling CC, Tannich E, Rolling T. High
- prevalence of asymptomatic malaria infections in adults, Ashanti Region, Ghana, 2018. Malar J.
- 834 2020;19(1):366. doi: 10.1186/s12936-020-03441-z. PubMed PMID: 33046056; PMCID:
- 835 PMC7552528.
- 836 22. Agonhossou R, Akoton R, Lagnika H, Djihinto OY, Sovegnon PM, Saizonou HD, Ntoumi
- 837 F, Wondji CS, Borrmann S, Adegnika AA, Djogbenou LS. P. falciparum msp1 and msp2 genetic
- diversity in P. falciparum single and mixed infection with P. malariae among the asymptomatic
- 839 population in Southern Benin. Parasitol Int. 2022;89:102590. doi: 10.1016/j.parint.2022.102590.
- 840 PubMed PMID: 35472441.
- 841 23. Trape JF, Rogier C, Konate L, Diagne N, Bouganali H, Canque B, Legros F, Badji A,
- Ndiaye G, Ndiaye P, et al. The Dielmo project: a longitudinal study of natural malaria infection
- and the mechanisms of protective immunity in a community living in a holoendemic area of
- 844 Senegal. Am J Trop Med Hyg. 1994;51(2):123-37. doi: 10.4269/ajtmh.1994.51.123. PubMed
- 845 PMID: 8074247.
- 846 24. Faye FB, Konate L, Rogier C, Trape JF. Plasmodium ovale in a highly malaria endemic
- area of Senegal. Trans R Soc Trop Med Hyg. 1998;92(5):522-5. doi: 10.1016/s0035-
- 848 9203(98)90900-2. PubMed PMID: 9861368.

- 849 25. Yerlikaya S, Campillo A, Gonzalez IJ. A Systematic Review: Performance of Rapid
- 850 Diagnostic Tests for the Detection of Plasmodium knowlesi, Plasmodium malariae, and
- Plasmodium ovale Monoinfections in Human Blood. J Infect Dis. 2018;218(2):265-76. doi:
- 852 10.1093/infdis/jiy150. PubMed PMID: 29554284; PMCID: PMC6009649.
- World Health Organization. Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale malaria 2016.
- 27. Diabate A, Dabire RK, Kengne P, Brengues C, Baldet T, Ouari A, Simard F, Lehmann T.
- Mixed swarms of the molecular M and S forms of Anopheles gambiae (Diptera: Culicidae) in
- 857 sympatric area from Burkina Faso. J Med Entomol. 2006;43(3):480-3. doi: 10.1603/0022-
- 858 2585(2006)43[480:msotmm]2.0.co;2. PubMed PMID: 16739404.
- 859 28. Fournet F, Cussac M, Ouari A, Meyer PE, Toe HK, Gouagna LC, Dabire RK. Diversity in
- anopheline larval habitats and adult composition during the dry and wet seasons in
- 861 Ouagadougou (Burkina Faso). Malar J. 2010;9:78. doi: 10.1186/1475-2875-9-78. PubMed
- 862 PMID: 20298619; PMCID: PMC2907872.
- 863 29. Wondji CS, Dabire RK, Tukur Z, Irving H, Djouaka R, Morgan JC. Identification and
- distribution of a GABA receptor mutation conferring dieldrin resistance in the malaria vector
- Anopheles funestus in Africa. Insect Biochem Mol Biol. 2011;41(7):484-91. doi:
- 866 10.1016/j.ibmb.2011.03.012. PubMed PMID: 21501685; PMCID: PMC3579012.
- 30. Gimonneau G, Pombi M, Choisy M, Morand S, Dabire RK, Simard F. Larval habitat
- segregation between the molecular forms of the mosquito Anopheles gambiae in a rice field
- area of Burkina Faso, West Africa. Med Vet Entomol. 2012;26(1):9-17. doi: 10.1111/j.1365-
- 870 2915.2011.00957.x. PubMed PMID: 21501199; PMCID: PMC3140611.
- 871 31. Namountougou M, Simard F, Baldet T, Diabate A, Ouedraogo JB, Martin T, Dabire RK.
- 872 Multiple insecticide resistance in Anopheles gambiae s.l. populations from Burkina Faso, West
- 873 Africa. PLoS One. 2012;7(11):e48412. Epub 2012/11/29. doi: 10.1371/journal.pone.0048412.
- 874 PubMed PMID: 23189131; PMCID: 3506617.
- 875 32. Dabire RK, Namountougou M, Sawadogo SP, Yaro LB, Toe HK, Ouari A, Gouagna LC,
- 876 Simard F, Chandre F, Baldet T, Bass C, Diabate A. Population dynamics of Anopheles gambiae
- 877 s.l. in Bobo-Dioulasso city: bionomics, infection rate and susceptibility to insecticides. Parasit
- 878 Vectors. 2012;5:127. Epub 2012/06/23. doi: 10.1186/1756-3305-5-127. PubMed PMID:
- 879 22721002; PMCID: 3424103.
- 880 33. Namountougou M, Diabate A, Etang J, Bass C, Sawadogo SP, Gnankinie O, Baldet T,
- 881 Martin T, Chandre F, Simard F, Dabire RK. First report of the L1014S kdr mutation in wild
- 882 populations of Anopheles gambiae M and S molecular forms in Burkina Faso (West Africa).
- 883 Acta Trop. 2013;125(2):123-7. Epub 2012/11/07. doi: 10.1016/j.actatropica.2012.10.012.
- 884 PubMed PMID: 23128044.
- 885 34. Niang A, Epopa PS, Sawadogo SP, Maiga H, Konate L, Faye O, Dabire RK, Tripet F,
- 886 Diabate A. Does extreme asymmetric dominance promote hybridization between Anopheles
- 887 coluzzii and Anopheles gambiae s.s. in seasonal malaria mosquito communities of West Africa?
- 888 Parasit Vectors. 2015;8:586. doi: 10.1186/s13071-015-1190-x. PubMed PMID: 26559354;
- 889 PMCID: PMC4642620.
- 890 35. Hidalgo K, Montazeau C, Siaussat D, Braman V, Trabalon M, Simard F, Renault D,
- Dabire RK, Mouline K. Distinct physiological, biochemical and morphometric adjustments in the
- malaria vectors Anopheles gambiae and A. coluzzii as means to survive dry season conditions
- in Burkina Faso. The Journal of experimental biology. 2018;221(Pt 6). doi: 10.1242/jeb.174433.
- 894 PubMed PMID: 29378815.
- 895 36. Gildenhard M, Rono EK, Diarra A, Boissiere A, Bascunan P, Carrillo-Bustamante P,
- 896 Camara D, Kruger H, Mariko M, Mariko R, Mireji P, Nsango SE, Pompon J, Reis Y, Rono MK,
- 897 Seda PB, Thailayil J, Traore A, Yapto CV, Awono-Ambene P, Dabire RK, Diabate A, Masiga D,
- 898 Catteruccia F, Morlais I, Diallo M, Sangare D, Levashina EA. Mosquito microevolution drives

- 899 Plasmodium falciparum dynamics. Nat Microbiol. 2019;4(6):941-7. doi: 10.1038/s41564-019-00414-9. PubMed PMID: 30911126; PMCID: PMC7613322.
- 901 37. Namountougou M, Soma DD, Kientega M, Balbone M, Kabore DPA, Drabo SF,
- 902 Coulibaly AY, Fournet F, Baldet T, Diabate A, Dabire RK, Gnankine O. Insecticide resistance
- 903 mechanisms in Anopheles gambiae complex populations from Burkina Faso, West Africa. Acta
- 904 Trop. 2019;197:105054. doi: 10.1016/j.actatropica.2019.105054. PubMed PMID: 31175862.
- 905 38. Epopa PS, Collins CM, North A, Millogo AA, Benedict MQ, Tripet F, Diabate A. Seasonal 906 malaria vector and transmission dynamics in western Burkina Faso. Malar J. 2019;18(1):113.
- 907 doi: 10.1186/s12936-019-2747-5. PubMed PMID: 30940141; PMCID: PMC6444393.
- 908 39. Soma DD, Zogo BM, Some A, Tchiekoi BN, Hien DFS, Pooda HS, Coulibaly S,
- 909 Gnambani JE, Ouari A, Mouline K, Dahounto A, Ouedraogo GA, Fournet F, Koffi AA, Pennetier
- 910 C, Moiroux N, Dabire RK. Anopheles bionomics, insecticide resistance and malaria transmission
- 911 in southwest Burkina Faso: A pre-intervention study. PLoS One. 2020;15(8):e0236920. doi:
- 912 10.1371/journal.pone.0236920. PubMed PMID: 32745085; PMCID: PMC7398507.
- 913 40. Dabire KR, Baldet T, Diabate A, Dia I, Costantini C, Cohuet A, Guiguemde TR,
- 914 Fontenille D. Anopheles funestus (Diptera: Culicidae) in a humid savannah area of western
- 915 Burkina Faso: bionomics, insecticide resistance status, and role in malaria transmission. J Med
- 916 Entomol. 2007;44(6):990-7. doi: 10.1603/0022-2585(2007)44[990:afdcia]2.0.co;2. PubMed
- 917 PMID: 18047197.
- 918 41. Soma DD, Poda SB, Hien AS, Namountougou M, Sangare I, Sawadogo JME, Fournet F,
- 919 Ouedraogo GA, Diabate A, Moiroux N, Dabire RK. Malaria vectors diversity, insecticide
- 920 resistance and transmission during the rainy season in peri-urban villages of south-western
- 921 Burkina Faso. Malar J. 2021;20(1):63. doi: 10.1186/s12936-020-03554-5. PubMed PMID:
- 922 33494779; PMCID: PMC7831184.
- 923 42. Taconet P, Porciani A, Soma DD, Mouline K, Simard F, Koffi AA, Pennetier C, Dabire
- 924 RK, Mangeas M, Moiroux N. Data-driven and interpretable machine-learning modeling to
- 925 explore the fine-scale environmental determinants of malaria vectors biting rates in rural Burkina
- 926 Faso. Parasit Vectors. 2021;14(1):345. doi: 10.1186/s13071-021-04851-x. PubMed PMID:
- 927 34187546; PMCID: PMC8243492.
- 928 43. Epopa PS, Millogo AA, Collins CM, North AR, Benedict MQ, Tripet F, O'Loughlin S,
- 929 Dabire RK, Ouedraogo GA, Diabate A. Anopheles gambiae (s.l.) is found where few are looking:
- 930 assessing mosquito diversity and density outside inhabited areas using diverse sampling
- 931 methods. Parasit Vectors. 2020;13(1):516. doi: 10.1186/s13071-020-04403-9. PubMed PMID:
- 932 33059722; PMCID: PMC7558606.
- 933 44. Mawejje HD, Kilama M, Kigozi SP, Musiime AK, Kamya M, Lines J, Lindsey SW, Smith
- 934 D, Dorsey G, Donnelly MJ, Staedke SG. Impact of seasonality and malaria control interventions
- on Anopheles density and species composition from three areas of Uganda with differing
- 936 malaria endemicity, Malaria J. 2021;20(1), doi: doi: 10.1186/s12936-021-03675-5.
- 937 45. O'Meara WP, Simmons R, Bullins P, Freedman B, Abel L, Mangeni J, Taylor SM, Obala
- 938 AA. Mosquito Exposure and Malaria Morbidity: A Microlevel Analysis of Household Mosquito
- 939 Populations and Malaria in a Population-Based Longitudinal Cohort in Western Kenya. J Infect
- 940 Dis. 2020;221(7):1176-84. doi: 10.1093/infdis/jiz561. PubMed PMID: 31665350; PMCID:
- 941 PMC7325711.
- 942 46. Morlais I, Nsango SE, Toussile W, Abate L, Annan Z, Tchioffo MT, Cohuet A, Awono-
- 943 Ambene PH, Fontenille D, Rousset F, Berry A. Plasmodium falciparum mating patterns and
- 944 mosquito infectivity of natural isolates of gametocytes. PLoS One. 2015;10(4):e0123777. doi:
- 945 10.1371/journal.pone.0123777. PubMed PMID: 25875840; PMCID: PMC4397039.
- 946 47. Das S, Muleba M, Stevenson JC, Pringle JC, Norris DE. Beyond the entomological
- 947 inoculation rate: characterizing multiple blood feeding behavior and Plasmodium falciparum
- 948 multiplicity of infection in Anopheles mosquitoes in northern Zambia. Parasit Vectors.

- 949 2017:10(1):45, doi: 10.1186/s13071-017-1993-z, PubMed PMID: 28122597; PMCID:
- 950 PMC5267472.
- 951 48. Kanatani S, Stiffler D, Bousema T, Yenokyan G, Sinnis P. Revisiting the Plasmodium
- 952 sporozoite inoculum and elucidating the efficiency with which malaria parasites progress
- 953 through the mosquito. Nat Commun. 2024;15(1):748. doi: 10.1038/s41467-024-44962-4.
- 954 PubMed PMID: 38272943; PMCID: PMC10811227.
- 955 49. Andolina C, Graumans W, Guelbeogo M, van Gemert GJ, Ramijth J, Harouna S,
- 956 Soumanaba Z, Stoter R, Vegte-Bolmer M, Pangos M, Sinnis P, Collins K, Staedke SG, Tiono
- 957 AB, Drakeley C, Lanke K, Bousema T. Quantification of sporozoite expelling by Anopheles
- 958 mosquitoes infected with laboratory and naturally circulating P. falciparum gametocytes. Elife.
- 959 2024;12. doi: 10.7554/eLife.90989. PubMed PMID: 38517746; PMCID: PMC10959522.
- 960 50. Pampiglioni S, Majori G, Petrangeli G, Romi R. Avermectins, MK-933 and MK-936, for mosquito control. Trans R Soc Trop Med Hyg. 1985;79:797-9.
- 962 51. Crump A, Omura S. Ivermectin, 'wonder drug' from Japan: the human use perspective.
- 963 Proceedings of the Japan Academy Series B, Physical and biological sciences. 2011;87(2):13-
- 964 28. Epub 2011/02/16. PubMed PMID: 21321478; PMCID: 3043740.
- 965 52. Bockarie MJ, Hii JL, Alexander ND, Bockarie F, Dagoro H, Kazura JW, Alpers MP. Mass
- treatment with ivermectin for filariasis control in Papua New Guinea: impact on mosquito
- 967 survival. Med Vet Entomol. 1999;13(2):120-3. PubMed PMID: 10484157.
- 968 53. Chaccour C, Lines J, Whitty CJ. Effect of ivermectin on Anopheles gambiae mosquitoes
- 969 fed on humans: the potential of oral insecticides in malaria control. J Infect Dis.
- 970 2010;202(1):113-6. PubMed PMID: 20482251.
- 971 54. Kobylinski KC, Sylla M, Chapman PL, Sarr MD, Foy BD. Ivermectin mass drug
- 972 administration to humans disrupts malaria parasite transmission in Senegalese villages. Am J
- 973 Trop Med Hyg. 2011;85(1):3-5. Epub 2011/07/08. doi: 10.4269/ajtmh.2011.11-0160. PubMed
- 974 PMID: 21734116; PMCID: 3122335.
- 975 55. Smit MR, Ochomo E, Aljayyoussi G, Kwambai T, Abong'o B, Bayoh N, Gimnig J,
- 976 Samuels A, Desai M, Phillips-Howard PA, Kariuki S, Wang D, Ward S, Ter Kuile FO. Efficacy
- 977 and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for
- 978 a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya. JMIR
- 979 Res Protoc. 2016;5(4):e213. doi: 10.2196/resprot.6617. PubMed PMID: 27856406; PMCID:
- 980 PMC5133431.
- 981 56. The Ivermectin Roadmappers, Billingsley P, Binka F, Chaccour C, Foy B, Gold S,
- 982 Gonzalez-Silva M, Jacobson J, Jagoe G, Jones C, Kachur P, Kobylinski K, Last A, Lavery JV,
- 983 Mabey D, Mboera D, Mbogo C, Mendez-Lopez A, Rabinovich NR, Rees S, Richards F, Rist C,
- 984 Rockwood J, Ruiz-Castillo P, Sattabongkot J, Saute F, Slater H, Steer A, Xia K, Zullinger R. A
- 985 Roadmap for the Development of Ivermectin as a Complementary Malaria Vector Control Tool.
- 986 Am J Trop Med Hyg. 2020;102(2s):3-24. doi: 10.4269/ajtmh.19-0620. PubMed PMID:
- 987 31971144; PMCID: PMC7008306.
- 988 57. Kositz C, Bradley J, Hutchins H, Last A, D'Alessandro U, Marks M. Broadening the
- 989 range of use cases for ivermectin a review of the evidence. Trans R Soc Trop Med Hyg.
- 990 2022;116(3):201-12. doi: 10.1093/trstmh/trab114. PubMed PMID: 34323283; PMCID:
- 991 PMC8890779.
- 992 58. Foy BD, Alout H, Seaman JA, Rao S, Magalhaes T, Wade M, Parikh S, Soma DD,
- 993 Sagna AB, Fournet F, Slater HC, Bougma R, Drabo F, Diabate A, Coulidiaty AGV, Rouamba N,
- 994 Dabire RK. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control
- of malaria (RIMDAMAL): a cluster-randomised trial. Lancet. 2019. doi: 10.1016/S0140-
- 996 6736(18)32321-3. PubMed PMID: 30878222.
- 997 59. Foy BD, Some A, Magalhaes T, Gray L, Rao S, Sougue E, Jackson CL, Kittelson J,
- 998 Slater HC, Bousema T, Da O, Coulidiaty AGV, Colt M, Wade M, Richards K, Some AF, Dabire
- 999 RK, Parikh S. Repeat Ivermectin Mass Drug Administrations for Malaria Control II: Protocol for a

- 1000 Double-blind, Cluster-Randomized, Placebo-Controlled Trial for the Integrated Control of
- 1001 Malaria. JMIR Res Protoc. 2023;12:e41197. doi: 10.2196/41197. PubMed PMID: 36939832;
- 1002 PMCID: PMC10132043.
- 1003 60. Dabira ED, Soumare HM, Lindsay SW, Conteh B, Ceesay F, Bradley J, Kositz C,
- 1004 Broekhuizen H, Kandeh B, Fehr AE, Nieto-Sanchez C, Ribera JM, Peeters Grietens K, Smit
- 1005 MR, Drakeley C, Bousema T, Achan J, D'Alessandro U. Mass Drug Administration With High-
- 1006 Dose Ivermectin and Dihydroartemisinin-Piperaquine for Malaria Elimination in an Area of Low
- 1007 Transmission With High Coverage of Malaria Control Interventions: Protocol for the MASSIV
- 1008 Cluster Randomized Clinical Trial. JMIR Res Protoc. 2020;9(11):e20904. doi: 10.2196/20904.
- 1009 PubMed PMID: 33211022; PMCID: PMC7714640.
- 1010 61. Hutchins H, Bradley J, Pretorius E, Teixeira da Silva E, Vasileva H, Jones RT, Ndiath
- 1011 MO, Dit Massire Soumare H, Mabey D, Nante EJ, Martins C, Logan JG, Slater H, Drakeley C,
- 1012 D'Alessandro U, Rodrigues A, Last AR. Protocol for a cluster randomised placebo-controlled
- trial of adjunctive ivermectin mass drug administration for malaria control on the Bijagos
- 1014 Archipelago of Guinea-Bissau: the MATAMAL trial. BMJ Open. 2023;13(7):e072347. doi:
- 1015 10.1136/bmjopen-2023-072347. PubMed PMID: 37419638; PMCID: PMC10335573.
- 1016 62. Chaccour C, Casellas A, Hammann F, Ruiz-Castillo P, Nicolas P, Montana J, Mael M,
- 1017 Selvaraj P, Duthaler U, Mrema S, Kakolwa M, Lyimo I, Okumu F, Marathe A, Schurch R,
- 1018 Elobolobo E, Sacoor C, Saute F, Xia K, Jones C, Rist C, Maia M, Rabinovich NR. BOHEMIA:
- 1019 Broad One Health Endectocide-based Malaria Intervention in Africa-a phase III cluster-
- 1020 randomized, open-label, clinical trial to study the safety and efficacy of ivermectin mass drug
- administration to reduce malaria transmission in two African settings. Trials. 2023;24(1):128.
- doi: 10.1186/s13063-023-07098-2. PubMed PMID: 36810194; PMCID: PMC9942013.
- 1023 63. World Health Organization. World Malaria Report 2023.
- 1024 64. Taylor SM, Messina JP, Hand CC, Juliano JJ, Muwonga J, Tshefu AK, Atua B, Emch M,
- 1025 Meshnick SR. Molecular malaria epidemiology: mapping and burden estimates for the
- 1026 Democratic Republic of the Congo, 2007. PLoS One. 2011;6(1):e16420. doi:
- 1027 10.1371/journal.pone.0016420. PubMed PMID: 21305011; PMCID: PMC3031549.
- 1028 65. Woldearegai TG, Lalremruata A, Nguyen TT, Gmeiner M, Veletzky L, Tazemda-Kuitsouc
- 1029 GB, Matsiegui PB, Mordmuller B, Held J. Characterization of Plasmodium infections among
- 1030 inhabitants of rural areas in Gabon. Sci Rep. 2019;9(1):9784. doi: 10.1038/s41598-019-46194-
- 1031 9. PubMed PMID: 31278305; PMCID: PMC6611864.
- 1032 66. Abdulraheem MA, Ernest M, Ugwuanyi I, Abkallo HM, Nishikawa S, Adeleke M,
- 1033 Orimadegun AE, Culleton R. High prevalence of Plasmodium malariae and Plasmodium ovale
- 1034 in co-infections with Plasmodium falciparum in asymptomatic malaria parasite carriers in
- 1035 southwestern Nigeria. Int J Parasitol. 2022;52(1):23-33. doi: 10.1016/j.ijpara.2021.06.003.
- 1036 PubMed PMID: 34390743.
- 1037 67. Amoah LE, Asare KK, Dickson D, Anang SF, Busayo A, Bredu D, Asumah G, Peprah N,
- 1038 Asamoah A, Abuaku B, Malm KL. Nationwide molecular surveillance of three Plasmodium
- species harboured by symptomatic malaria patients living in Ghana. Parasit Vectors.
- 1040 2022;15(1):40. doi: 10.1186/s13071-022-05153-6. PubMed PMID: 35090545; PMCID:
- 1041 PMC8796507.
- 1042 68. Amoah LE, Donu D, Abuaku B, Ahorlu C, Arhinful D, Afari E, Malm K, Koram KA.
- 1043 Probing the composition of Plasmodium species contained in malaria infections in the Eastern
- 1044 region of Ghana. BMC Public Health. 2019;19(1):1617. doi: 10.1186/s12889-019-7989-1.
- 1045 PubMed PMID: 31791319; PMCID: PMC6889690.
- 1046 69. Nguiffo-Nguete D, Nongley Nkemngo F, Ndo C, Agbor JP, Boussougou-Sambe ST,
- 1047 Salako Djogbenou L, Ntoumi F, Adegnika AA, Borrmann S, Wondji CS. Plasmodium malariae
- 1048 contributes to high levels of malaria transmission in a forest-savannah transition area in
- 1049 Cameroon. Parasit Vectors. 2023;16(1):31. doi: 10.1186/s13071-022-05635-7. PubMed PMID:
- 1050 36698132; PMCID: PMC9875470.

- 1051 70. Oriero EC, Olukosi AY, Oduwole OA, Diimde A, D'Alessandro U, Meremikwu MM.
- 1052 Amambua-Ngwa A. Seroprevalence and Parasite Rates of Plasmodium malariae in a High
- Malaria Transmission Setting of Southern Nigeria. Am J Trop Med Hyg. 2020;103(6):2208-16.
- 1054 doi: 10.4269/ajtmh.20-0593. PubMed PMID: 33124531; PMCID: PMC7695047.
- 1055 71. Quaye IK, Aleksenko L, Oeuvray C, Yewhalaw D, Duah N, Gyan B, Haiyambo DH,
- 1056 Dongho GBD, Torgby RA, Amoah L, Hamid MA, Worku S, Bahiti AA, Pasquale HA, Bitshi M,
- 1057 Troare I, Diarra A, Njunju E, Cisse M, Soulama I, Savadogo RJ, Issifou S, Niangaly A, Dembele
- 1058 L, Greco B. The Pan African Vivax and Ovale Network (PAVON): Refocusing on Plasmodium
- 1059 vivax, ovale and asymptomatic malaria in sub-Saharan Africa. Parasitol Int. 2021;84:102415.
- 1060 doi: 10.1016/j.parint.2021.102415. PubMed PMID: 34216801.
- 1061 72. Sendor R, Mitchell CL, Chacky F, Mohamed A, Mhamilawa LE, Molteni F, Nyinondi S,
- 1062 Kabula B, Mkali H, Reaves EJ, Serbantez N, Kitojo C, Makene T, Kyaw T, Muller M, Mwanza A,
- 1063 Eckert EL, Parr JB, Lin JT, Juliano JJ, Ngasala B. Similar Prevalence of Plasmodium falciparum
- and Non-P. falciparum Malaria Infections among Schoolchildren, Tanzania(1). Emerg Infect Dis.
- 1065 2023;29(6):1143-53. doi: 10.3201/eid2906.221016. PubMed PMID: 37209670; PMCID:
- 1066 PMC10202886.
- 1067 73. Hawadak J, Dongang Nana RR, Singh V. Global trend of Plasmodium malariae and
- 1068 Plasmodium ovale spp. malaria infections in the last two decades (2000-2020): a systematic
- 1069 review and meta-analysis. Parasit Vectors. 2021;14(1):297. doi: 10.1186/s13071-021-04797-0.
- 1070 PubMed PMID: 34082791; PMCID: PMC8173816.
- 1071 74. Sagna AB, Zela L, Ouedraogo COW, Pooda SH, Porciani A, Furnival-Adams J, Lado P,
- 1072 Some AF, Pennetier C, Chaccour CJ, Dabire RK, Mouline K. Ivermectin as a novel malaria
- 1073 control tool: Getting ahead of the resistance curse. Acta Trop. 2023;245:106973. doi:
- 1074 10.1016/j.actatropica.2023.106973. PubMed PMID: 37352998.
- 1075 75. Taconet P, Zogo B, Soma DD, Ahoua Alou LP, Mouline K, Dabire RK, Amanan Koffi A,
- 1076 Pennetier C, Moiroux N. Anopheles sampling collections in the health districts of Korhogo (Cote
- 1077 d'Ivoire) and Diebougou (Burkina Faso) between 2016 and 2018. GigaByte.
- 1078 2023;2023:gigabyte83. doi: 10.46471/gigabyte.83. PubMed PMID: 37408730; PMCID:
- 1079 PMC10318348.
- 1080 76. McMahon A, Franca CMB, Wimberly MC. Comparing Satellite and Ground-Based
- 1081 Measurements of Environmental Suitability for Vector Mosquitoes in an Urban Landscape. J
- 1082 Med Entomol. 2022;59(6):1936-46. doi: 10.1093/jme/tjac145. PubMed PMID: 36189969;
- 1083 PMCID: PMC9667728.
- 1084 77. Snounou G, Pinheiro L, Goncalves A, Fonseca L, Dias F, Brown KN, do Rosario VE.
- The importance of sensitive detection of malaria parasites in the human and insect hosts in
- 1086 epidemiological studies, as shown by the analysis of field samples from Guinea Bissau. Trans R
- 1087 Soc Trop Med Hyg. 1993;87(6):649-53. doi: 10.1016/0035-9203(93)90274-t. PubMed PMID:
- 1088 8296364.
- 1089 78. Nsobya SL, Parikh S, Kironde F, Lubega G, Kamya MR, Rosenthal PJ, Dorsey G.
- 1090 Molecular evaluation of the natural history of asymptomatic parasitemia in Ugandan children. J
- 1091 Infect Dis. 2004;189(12):2220-6. doi: 10.1086/421281. PubMed PMID: 15181569.
- 1092 79. Murphy SC, Shott JP, Parikh S, Etter P, Prescott WR, Stewart VA. Malaria diagnostics in
- 1093 clinical trials. Am J Trop Med Hyg. 2013;89(5):824-39. doi: 10.4269/ajtmh.12-0675. PubMed
- 1094 PMID: 24062484; PMCID: PMC3820323.
- 1095 80. Beadle C, Long GW, Weiss WR, McElroy PD, Maret SM, Oloo AJ, Hoffman SL.
- 1096 Diagnosis of malaria by detection of Plasmodium falciparum HRP-2 antigen with a rapid dipstick
- 1097 antigen-capture assay. Lancet. 1994;343(8897):564-8. doi: 10.1016/s0140-6736(94)91520-2.
- 1098 PubMed PMID: 7906328.
- 1099 81. Poti KE, Sullivan DJ, Dondorp AM, Woodrow CJ. HRP2: Transforming Malaria
- Diagnosis, but with Caveats. Trends Parasitol. 2020;36(2):112-26. doi:
- 1101 10.1016/j.pt.2019.12.004. PubMed PMID: 31848119.

- 1102 82. WHO, World Malaria Report 2023, Geneva: World Health Organization, 2023.
- 1103 83. Singh B. Molecular methods for diagnosis and epidemiological studies of parasitic
- 1104 infections. Int J Parasitol. 1997;27(10):1135-45. doi: 10.1016/s0020-7519(97)00111-2. PubMed 1105 PMID: 9394184.
- 1106 84. Abba K, Deeks JJ, Olliaro P, Naing CM, Jackson SM, Takwoingi Y, Donegan S, Garner
- 1107 P. Rapid diagnostic tests for diagnosing uncomplicated P. falciparum malaria in endemic
- 1108 countries. The Cochrane database of systematic reviews. 2011;2011(7):CD008122. doi:
- 1109 10.1002/14651858.CD008122.pub2. PubMed PMID: 21735422; PMCID: PMC6532563.
- 1110 85. Maltha J, Gillet P, Jacobs J. Malaria rapid diagnostic tests in endemic settings. Clin
- 1111 Microbiol Infect. 2013;19(5):399-407. doi: 10.1111/1469-0691.12151. PubMed PMID:
- 1112 23438048.
- 1113 86. Jimenez A, Rees-Channer RR, Perera R, Gamboa D, Chiodini PL, Gonzalez IJ, Mayor
- 1114 A, Ding XC. Analytical sensitivity of current best-in-class malaria rapid diagnostic tests. Malar J.
- 1115 2017;16(1):128. doi: 10.1186/s12936-017-1780-5. PubMed PMID: 28340585; PMCID:
- 1116 PMC5366122.
- 1117 87. Farcas GA, Zhong KJ, Lovegrove FE, Graham CM, Kain KC. Evaluation of the Binax
- 1118 NOW ICT test versus polymerase chain reaction and microscopy for the detection of malaria in
- 1119 returned travelers. Am J Trop Med Hyg. 2003;69(6):589-92. PubMed PMID: 14740873.
- 1120 88. Ratsimbasoa A, Randriamanantena A, Raherinjafy R, Rasoarilalao N, Menard D. Which
- malaria rapid test for Madagascar? Field and laboratory evaluation of three tests and expert
- 1122 microscopy of samples from suspected malaria patients in Madagascar. Am J Trop Med Hyg.
- 1123 2007;76(3):481-5. PubMed PMID: 17360871.
- 1124 89. Khairnar K, Martin D, Lau R, Ralevski F, Pillai DR. Multiplex real-time quantitative PCR,
- 1125 microscopy and rapid diagnostic immuno-chromatographic tests for the detection of
- 1126 Plasmodium spp: performance, limit of detection analysis and quality assurance. Malar J.
- 1127 2009;8:284. doi: 10.1186/1475-2875-8-284. PubMed PMID: 20003199; PMCID: PMC2796674.
- 1128 90. Sokhna C, Cisse B, Ba el H, Milligan P, Hallett R, Sutherland C, Gaye O, Boulanger D,
- 1129 Simondon K, Simondon F, Targett G, Lines J, Greenwood B, Trape JF. A trial of the efficacy,
- safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive
- 1131 treatment for malaria in Senegalese children. PLoS One. 2008;3(1):e1471. doi:
- 1132 10.1371/journal.pone.0001471. PubMed PMID: 18213379; PMCID: PMC2198946.
- 1133 91. Dicko A, Diallo AI, Tembine I, Dicko Y, Dara N, Sidibe Y, Santara G, Diawara H, Conare
- 1134 T, Djimde A, Chandramohan D, Cousens S, Milligan PJ, Diallo DA, Doumbo OK, Greenwood B.
- 1135 Intermittent preventive treatment of malaria provides substantial protection against malaria in
- 1136 children already protected by an insecticide-treated bednet in Mali: a randomised, double-blind,
- 1137 placebo-controlled trial. PLoS Med. 2011;8(2):e1000407. doi: 10.1371/journal.pmed.1000407.
- 1138 PubMed PMID: 21304923; PMCID: PMC3032550.
- 1139 92. Tagbor H, Antwi GD, Acheampong PR, Bart Plange C, Chandramohan D, Cairns M.
- 1140 Seasonal malaria chemoprevention in an area of extended seasonal transmission in Ashanti,
- 1141 Ghana: an individually randomised clinical trial. Trop Med Int Health. 2016;21(2):224-35. doi:
- 1142 10.1111/tmi.12642. PubMed PMID: 26578353; PMCID: PMC4982104.
- 1143 93. Cisse B, Ba EH, Sokhna C, JL ND, Gomis JF, Dial Y, Pitt C, M ND, Cairns M, Faye E, M
- 1144 ND, Lo A, Tine R, Faye S, Faye B, Sy O, Konate L, Kouevijdin E, Flach C, Faye O, Trape JF,
- 1145 Sutherland C, Fall FB, Thior PM, Faye OK, Greenwood B, Gaye O, Milligan P. Effectiveness of
- 1146 Seasonal Malaria Chemoprevention in Children under Ten Years of Age in Senegal: A Stepped-
- 1147 Wedge Cluster-Randomised Trial. PLoS Med. 2016;13(11):e1002175. doi:
- 1148 10.1371/journal.pmed.1002175. PubMed PMID: 27875528; PMCID: PMC5119693.
- 1149 94. Diawara SI, Konate D, Kayentao K, Mihigo J, Shaffer JG, Sangare M, Ndabamenye P,
- 1150 Swedberg E, Garg LW, Gamache N, Keita B, Kamate B, Ndaruhutse P, Kone D, Sanogo V,
- Tounkara M, Diakite M, Doumbia S, Eckert E. Effect of seasonal malaria chemoprevention in
- 1152 children between 5 and 9 years old in Kita and Bafoulabe districts, Mali. Parasite Epidemiol

- 1153 Control. 2022;18:e00258. doi: 10.1016/j.parepi.2022.e00258. PubMed PMID: 35789762;
- 1154 PMCID: PMC9249800.
- 1155 95. Ansah PO, Ansah NA, Malm K, Awuni D, Peprah N, Dassah S, Yarig S, Manful C,
- 1156 Agbenyeri J, Awoonor-Williams J, Ofosu W, Oduro AR. Evaluation of pilot implementation of
- 1157 seasonal malaria chemoprevention on morbidity in young children in Northern Sahelian Ghana.
- 1158 Malar J. 2021;20(1):440. doi: 10.1186/s12936-021-03974-x. PubMed PMID: 34794431; PMCID:
- 1159 PMC8600740.
- 1160 96. Chandramohan D, Zongo I, Sagara I, Cairns M, Yerbanga RS, Diarra M, Nikiema F,
- 1161 Tapily A, Sompougdou F, Issiaka D, Zoungrana C, Sanogo K, Haro A, Kaya M, Sienou AA,
- 1162 Traore S, Mahamar A, Thera I, Diarra K, Dolo A, Kuepfer I, Snell P, Milligan P, Ockenhouse C,
- 1163 Ofori-Anyinam O, Tinto H, Djimde A, Ouedraogo JB, Dicko A, Greenwood B. Seasonal Malaria
- 1164 Vaccination with or without Seasonal Malaria Chemoprevention. N Engl J Med.
- 1165 2021;385(11):1005-17. doi: 10.1056/NEJMoa2026330. PubMed PMID: 34432975.
- 1166 97. Coldiron ME, Assao B, Guindo O, Sayinzoga-Makombe N, Koscalova A, Sterk E, Quere
- 1167 M, Ciglenecki I, Mumina A, Atti S, Langendorf C, Grais RF. Prevalence of malaria in an area
- receiving seasonal malaria chemoprevention in Niger. Malar J. 2021;20(1):419. doi:
- 1169 10.1186/s12936-021-03953-2. PubMed PMID: 34689782; PMCID: PMC8543849.
- 1170 98. Faye FB, Spiegel A, Tall A, Sokhna C, Fontenille D, Rogier C, Trape JF. Diagnostic
- 1171 criteria and risk factors for Plasmodium ovale malaria. J Infect Dis. 2002;186(5):690-5. doi:
- 1172 10.1086/342395. PubMed PMID: 12195357.
- 1173 99. Collins WE, Jeffery GM. Plasmodium malariae: parasite and disease. Clin Microbiol Rev.
- 1174 2007;20(4):579-92. doi: 10.1128/CMR.00027-07. PubMed PMID: 17934075; PMCID:
- 1175 PMC2176047.
- 1176 100. Collins WE, Jeffery GM. Plasmodium ovale: parasite and disease. Clin Microbiol Rev.
- 1177 2005;18(3):570-81. doi: 10.1128/CMR.18.3.570-581.2005. PubMed PMID: 16020691; PMCID:
- 1178 PMC1195966.
- 1179 101. Nambunga IH, Ngowo HS, Mapua SA, Hape EE, Msugupakulya BJ, Msaky DS,
- 1180 Mhumbira NT, McHwembo KR, Tamayamali GZ, Mlembe SV, Njalambaha RM, Lwetoijera DW,
- 1181 Finda MF, Govella NJ, Matoke-Muhia D, Kaindoa EW, Okumu FO. Aquatic habitats of the
- malaria vector Anopheles funestus in rural south-eastern Tanzania. Malar J. 2020;19(1):219.
- 1183 doi: 10.1186/s12936-020-03295-5. PubMed PMID: 32576200; PMCID: PMC7310514.
- 1184 102. Scott TW, Takken W. Feeding strategies of anthropophilic mosquitoes result in
- 1185 increased risk of pathogen transmission. Trends Parasitol. 2012;28(3):114-21. doi:
- 1186 10.1016/j.pt.2012.01.001. PubMed PMID: 22300806.
- 1187 103. Bartholomay LC, Michel K. Mosquito Immunobiology: The Intersection of Vector Health
- and Vector Competence. Annu Rev Entomol. 2018;63:145-67. doi: 10.1146/annurev-ento-
- 1189 010715-023530. PubMed PMID: 29324042.
- 1190 104. McKenzie FE, Bossert WH. Mixed-species Plasmodium infections of Anopheles
- 1191 (Diptera:Culicidae). J Med Entomol. 1997;34(4):417-25. doi: 10.1093/jmedent/34.4.417.
- 1192 PubMed PMID: 9220675; PMCID: PMC2500223.
- 1193 105. Shaw WR, Marcenac P, Catteruccia F. Plasmodium development in Anopheles: a tale of
- 1194 shared resources. Trends Parasitol. 2022;38(2):124-35. doi: 10.1016/j.pt.2021.08.009. PubMed
- 1195 PMID: 34548252; PMCID: PMC8758519.
- 1196 106. Arez AP, Pinto J, Palsson K, Snounou G, Jaenson TG, do Rosario VE. Transmission of
- 1197 mixed Plasmodium species and Plasmodium falciparum genotypes. Am J Trop Med Hyg.
- 1198 2003;68(2):161-8. PubMed PMID: 12641406.
- 1199 107. Imwong M, Nakeesathit S, Day NP, White NJ. A review of mixed malaria species
- 1200 infections in anopheline mosquitoes. Malar J. 2011;10:253. doi: 10.1186/1475-2875-10-253.
- 1201 PubMed PMID: 21880138; PMCID: PMC3201030.
- 1202 108. Balasubramanian S, Rahman RS, Lon C, Parobek C, Ubalee R, Hathaway N,
- 1203 Kuntawunginn W, My M, Vy D, Saxe J, Lanteri C, Lin FC, Spring M, Meshnick SR, Juliano JJ,

- 1204 Saunders DL. Lin JT. Efficient Transmission of Mixed Plasmodium falciparum/vivax Infections
- 1205 From Humans to Mosquitoes. J Infect Dis. 2020;221(3):428-37. doi: 10.1093/infdis/jiz388.
- 1206 PubMed PMID: 31549156; PMCID: PMC7184918.
- 1207 109. Robinson A, Busula AO, Voets MA, Beshir KB, Caulfield JC, Powers SJ, Verhulst NO,
- 1208 Winskill P, Muwanguzi J, Birkett MA, Smallegange RC, Masiga DK, Mukabana WR, Sauerwein
- 1209 RW, Sutherland CJ, Bousema T, Pickett JA, Takken W, Logan JG, de Boer JG. Plasmodium-
- 1210 associated changes in human odor attract mosquitoes. Proc Natl Acad Sci U S A.
- 1211 2018;115(18):E4209-E18. doi: 10.1073/pnas.1721610115. PubMed PMID: 29666273; PMCID:
- 1212 PMC5939094.
- 1213 110. MR4. Methods in Anopheles Research 2014. Available from:
- 1214 https://www.beiresources.org/portals/2/MR4/MR4 Publications/Methods%20in%20Anopheles%
- 1215 <u>20Research%202014/2014MethodsinAnophelesResearchManualFullVersionv2tso.pdf.</u>
- 1216 111. Burkot TR, Zavala F, Gwadz RW, Collins FH, Nussenzweig RS, Roberts DR.
- 1217 Identification of malaria-infected mosquitoes by a two-site enzyme-linked immunosorbent assay.
- 1218 Am J Trop Med Hyg. 1984;33(2):227-31. doi: 10.4269/ajtmh.1984.33.227. PubMed PMID:
- 1219 6370003.
- 1220 112. Beier JC, Perkins PV, Koros JK, Onyango FK, Gargan TP, Wirtz RA, Koech DK, Roberts
- 1221 CR. Malaria sporozoite detection by dissection and ELISA to assess infectivity of afrotropical
- 1222 Anopheles (Diptera: Culicidae). J Med Entomol. 1990;27(3):377-84. doi:
- 1223 10.1093/jmedent/27.3.377. PubMed PMID: 2185363.
- 1224 113. Durnez L, Van Bortel W, Denis L, Roelants P, Veracx A, Trung HD, Sochantha T,
- 1225 Coosemans M. False positive circumsporozoite protein ELISA: a challenge for the estimation of
- the entomological inoculation rate of malaria and for vector incrimination. Malar J. 2011;10:195.
- 1227 doi: 10.1186/1475-2875-10-195. PubMed PMID: 21767376; PMCID: PMC3160429.
- 1228 114. Echeverry DF, Deason NA, Makuru V, Davidson J, Xiao H, Niedbalski J, Yu X,
- 1229 Stevenson JC, Bugoro H, Aparaimo A, Reuben H, Cooper R, Burkot TR, Russell TL, Collins FH,
- 1230 Lobo NF. Fast and robust single PCR for Plasmodium sporozoite detection in mosquitoes using
- the cytochrome oxidase I gene. Malar J. 2017;16(1):230. doi: 10.1186/s12936-017-1881-1.
- 1232 PubMed PMID: 28569159; PMCID: PMC5452387.
- 1233 115. Ogola EO, Fillinger U, Ondiba IM, Villinger J, Masiga DK, Torto B, Tchouassi DP.
- 1234 Insights into malaria transmission among Anopheles funestus mosquitoes, Kenya. Parasit
- 1235 Vectors. 2018;11(1):577. doi: 10.1186/s13071-018-3171-3. PubMed PMID: 30400976; PMCID:
- 1236 PMC6219006.
- 1237 116. Foley DH, Harrison G, Murphy JR, Dowler M, Rueda LM, Wilkerson RC. Mosquito
- 1238 bisection as a variable in estimates of PCR-derived malaria sporozoite rates. Malar J.
- 1239 2012;11:145. doi: 10.1186/1475-2875-11-145. PubMed PMID: 22551078; PMCID:
- 1240 PMC3411414.
- 1241 117. Diagne N, Fontenille D, Konate L, Faye O, Lamizana MT, Legros F, Molez JF, Trape JF.
- 1242 [Anopheles of Senegal. An annotated and illustrated list]. Bull Soc Pathol Exot. 1994;87(4):267-
- 1243 77. PubMed PMID: 7866049.
- 1244 118. Gillies MT, Coetzee M. A supplement to the Anophelinae of Africa South of the Sahara
- 1245 (Afrotropical Region). S Afr Inst Med Res. 1987:143.
- 1246 119. Wilkins EE, Howell PI, Benedict MQ. IMP PCR primers detect single nucleotide
- 1247 polymorphisms for Anopheles gambiae species identification, Mopti and Savanna rDNA types,
- and resistance to dieldrin in Anopheles arabiensis. Malar J. 2006;5:125. doi: 10.1186/1475-
- 1249 2875-5-125. PubMed PMID: 17177993; PMCID: PMC1769388.
- 1250 120. Koekemoer LL, Kamau L, Hunt RH, Coetzee M. A cocktail polymerase chain reaction
- assay to identify members of the Anopheles funestus (Diptera: Culicidae) group. Am J Trop Med
- 1252 Hyg. 2002;66(6):804-11. doi: 10.4269/ajtmh.2002.66.804. PubMed PMID: 12224596.
- 1253 121. Maddison WP, Maddison DR. Mesquite: a modular system for evolutionary analysis.
- 1254 2021.

- 1255 122. Hofmann N, Mwingira F, Shekalaghe S, Robinson LJ, Mueller I, Felger I. Ultra-sensitive
- detection of Plasmodium falciparum by amplification of multi-copy subtelomeric targets. PLoS
- 1257 Med. 2015;12(3):e1001788. doi: 10.1371/journal.pmed.1001788. PubMed PMID: 25734259;
- 1258 PMCID: PMC4348198.
- 1259 123. Phuong M, Lau R, Ralevski F, Boggild AK. Sequence-based optimization of a
- 1260 quantitative real-time PCR assay for detection of Plasmodium ovale and Plasmodium malariae.
- 1261 J Clin Microbiol. 2014;52(4):1068-73. doi: 10.1128/JCM.03477-13. PubMed PMID: 24430459;
- 1262 PMCID: PMC3993485.

- 1263 124. Kent RJ, Norris DE. Identification of mammalian blood meals in mosquitoes by a
- multiplexed polymerase chain reaction targeting cytochrome B. Am J Trop Med Hyg.
- 1265 2005;73(2):336-42. PubMed PMID: 16103600; PMCID: PMC4147110.